Algorhythm Holdings, Inc. (RIME): Nasdaq/NYSE listing notice — Algorhythm receives Nasdaq bid-price deficiency notice; 180-day cure period

Algorhythm Holdings, Inc.

Closing bid price below $1.00 for 30 consecutive business days ended June 15, 2026.
Compliance period runs to December 14, 2026; must close at $1.00+ for 10 consecutive days.
If not cured in 180 days, may be eligible for additional 180-day period with reverse stock split.
No immediate impact on listing; shares continue trading under RIME.

item 3.01

Featured in Daily 8-K Digest

Selected #6 for 2026-06-18. Read digest

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Algorhythm Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 16, 2026, Algorhythm Holdings, Inc. (the “Company”) received a letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock (Nasdaq symbol: RIME) for the 30 consecutive business days from May 4, 2026 to June 15, 2026, the Company no longer meets the minimum bid price requirement of $1.00 per share set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The Notification Letter states that the Company ha

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Algorhythm Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-029347

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.